[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aaa---abdominal-aortic-aneurysm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aaa---abdominal-aortic-aneurysm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,70,99,136,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100631776","nectero-east-system-retreatment-study-100631776",false,"NCT07505082","Nectero EAST System Retreatment Study","A Clinical Pilot Study to Evaluate the Safety and Clinical Utility of Retreatment With the Nectero EAST System for Stabilization of Abdominal Aortic Aneurysms","Inclusion Criteria:\n\n1. Received initial Nectero EAST System treatment under protocol CTP-001.\n2. Males and females ≥21 to ≤85 years of age. Females must be of non-childbearing potential (menopause or sterilization).\n3. Subject understands the purpose of the trial, agrees to voluntarily participate in the trial, signs the informed consent and is willing to complete the follow-up according to the requirements of the protocol.\n4. Infrarenal atherosclerotic fusiform abdominal aortic aneurysm ≤5.3 cm (male) and ≤4.8 cm (female).\n5. Infrarenal aortic neck ≥ 15 mm in length and ≤ 29 mm in diameter.\n6. Overall AAA treatment length (distal renal artery to distal inferior margin of the aneurysm) not to exceed 130 mm.\n7. Iliac and femoral artery access, vessel size and morphology allow endovascular access of 14F (or larger) introducer sheaths and catheters.\n8. Subject meets American Society of Anesthesiology (ASA) grade 1 through 3 criteria, inclusive.\n9. Subject has \\> two-year life expectancy.\n10. Subject is able and willing to comply with all required follow-up clinic visits including CT scans (screening, 6, 12, 24 months) and blood draws.\n\nExclusion Criteria:\n\n1. Subject has an acutely ruptured, leaking, dissecting or emergent aneurysm.\n2. Subject has a symptomatic infrarenal abdominal aortic aneurysm.\n3. Subject has a mycotic or infected aneurysm.\n4. Subject has current vascular injury due to trauma.\n5. Subject's aneurysm is thoracic, suprarenal or juxtarenal.\n6. Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm.\n7. Subject has anatomy of diffuse, ulcerated, or extensive (shaggy) thrombus in the neck of the AAA, that in the opinion of the vascular surgeon\u002Finvestigator, could result in embolization of the thrombus.\n8. Subject has anatomy of calcification, and\u002For plaque within the ilio-femoral arteries or severe infrarenal neck angulation that may compromise or does not allow delivery of the Introducer Sheath or the delivery catheter of the Nectero EAST System.\n9. Subject has had a myocardial infarction within six (6) months prior to enrollment or elevated CK enzymes or troponin indicative of an evolving MI prior to procedure.\n10. Subject has current angina, unstable angina, or other active cardiac condition such as congestive heart failure III and IV, atrial arrhythmia, ventricular arrhythmia, or valvular disease, requiring intervention.\n11. Subject has undergone other major surgery within the 30 days prior to enrollment.\n12. Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months.\n13. Known allergy to contrast material that cannot be adequately premedicated, delivery system materials (i.e., nylon, polyurethane) and\u002For pentagalloylglucose (PGG).\n14. Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.\n15. Subject has connective tissue\u002Fcollagen disorder (e.g., Marfan syndrome, vascular Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, Eaton Syndrome, Bessel-Hagen disease, etc.).\n16. Known contraindication to undergoing angiography or receiving systemic anticoagulation during the procedure.\n17. Subject has active systemic infection.\n18. Subject is participating in another research trial that could interfere with the results of the trial (e.g., drug trial).\n19. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from participation in the trial and to undergo the procedures and evaluations pre- and post-treatment.\n20. Subject has dialysis dependent renal failure or baseline serum creatinine level \\>2.5mg\u002FdL or eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m2.\n21. Subjects with aminotransferase (ALT and\u002For AST) which is ≥1.5x upper limit of normal (ULN) or TB is out of normal range for the evaluating laboratory.\n22. Subjects that may not tolerate the lowering of their systolic blood pressure to approximately 100mmHg, should not be considered for this study or treated using the Nectero EAST System.\n23. Subjects that may not be able to tolerate transient occlusion of the aorta should not be considered for this study.\n24. Subjects with saccular AAA.\n25. Subjects with rapidly expanding AAA (previous diameter increases of ≥0.5 cm in 6-months or ≥1 cm in 1 year) as these should be evaluated for immediate repair.\n26. Subjects who are not suitable for the Nectero EAST System treatment, as determined by the investigator.\n27. Subjects with INR out of normal range for the evaluating laboratory for a subject not on anti-coagulant therapy; or INR \\>3 for a subject on anti-coagulant therapy.\n28. Subjects with active\u002Facute or a history of unstable chronic liver disease or current liver disease including but not limited to liver transplant, known genetic disorders such as Gilbert syndrome or other liver diseases.\n29. Subjects with cirrhosis (e.g., known history or new clinical diagnosis by elastography with a fibrosis score of F3 or F4 and\u002For steatosis grade of S3).\n30. Subjects with uncontrolled alcohol use disorder or current alcohol use putting them at risk of liver disease: including consumption of above one standard drink per day for women and two standard drinks per day for men.\n31. Subjects with known right-sided heart failure or pathologically dilated inferior vena cava or hepatic veins indicative of congestive hepatopathy.","ALL","21 Years","85 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an exploratory pilot study to evaluate the safety and clinical utility of retreatment with an investigational combination product called the Nectero EAST System to treat Abdominal Aortic Aneurysms or AAA.",[27,28,29],"AAA - Abdominal Aortic Aneurysm","Aorta Aneurysm","Dilation Aorta",[31,32],"Abdominal Aorta","Aneurysm","RECRUITING","2026-05-21",{"date":36,"type":37},"2026-05-26","ACTUAL",{"date":39,"type":37},"2026-03-03",{"date":41,"type":21},"2029-02",{"name":43,"class":44},"Nectero Medical, Inc.","INDUSTRY",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100634501","data-collection-of-the-tuva-bx-and-icover-stent-grafts-implanted-during-branched-endovascular-aortic-repair-bevar-100634501","NCT07540507","Data Collection of the TUVA BX and iCover Stent Grafts Implanted During Branched Endovascular Aortic Repair (BEVAR)","Retrospective Data Collection of the TUVA BX and iCover Stent Grafts Implanted During Branched Endovascular Aortic Repair (BEVAR)","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of index procedure\n* Patients must have a completed treatment of TAAA or complex AAA treated with E-nside TAAA Multibranch Stent Graft System (E-nside) or E-xtra Design MultiBranch Stent Graft System (EDM) and with at least one target vessel (CT, SMA, LRA, RRA) bridged with any combination of TUVA BX or iCover.\n* The index procedure was performed after January 2020.\n* The patient is not deceased and has already completed or expects to complete the 1 year follow-up visit prior to July 2026; or the patient died.\n* Patients have been consented according to the local regulation.\n\nExclusion Criteria:\n\n* Patient treated for ruptured aneurysm or who were otherwise hemodynamically unstable before the procedure.\n* Patients enrolled in an investigational study that could confound registry endpoints at index procedure.\n* Patients who developed a new onset of aortic disease (in any segment) since index procedure, potentially having an impact on the performance of the TAAA or TUVA BX \u002FiCover, devices at the discretion of the investigator","18 Years",{"count":55,"type":21},105,"OBSERVATIONAL","The study aims to check whether the TUVA BX and iCover stent grafts are safe and work well when used during a specific type of minimally invasive surgery (BEVAR) to treat complex aortic aneurysms.\n\nIt is a retrospective study and it is conducted at multiple hospitals and does not include a comparison group.\n\nResearchers will collect and review patient data from medical records, starting from the original procedure and continuing through the 1-year follow-up visit.",[59,27],"TAAA","NOT_YET_RECRUITING","2026-04-14",{"date":63,"type":37},"2026-04-20",{"date":61,"type":21},{"date":66,"type":21},"2026-12-31",{"name":68,"class":44},"JOTEC GmbH",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":56,"phases":4,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100532904","endovascular-aaa-intervention-using-the-gore-excluder-conformable-aaa-endoprosthesis-or-iliac-branch-endoprosthesis-100532904","NCT06218875","Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis","Assessment of Long Term, Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis","Inclusion Criteria:\n\n1. Patient or legally authorized representative (LAR) provides written authorization and\u002For consent per institution and geographical requirements\n2. Patient has been or is intended to be treated with an eligible registry device\n3. Patient is age ≥ 18 years at time of informed consent signature.\n\nExclusion Criteria:\n\n1. Patient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures.\n2. Patient with exclusion criteria required by local law.\n3. Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol.",{"count":78,"type":21},2000,"10 Years","A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice.",[27],[32,83,84,85,86,87,88],"Aneurysm Repair","Endovascular","EVAR","Endoprosthesis","Aortic","Aortic Repair","2026-02-02",{"date":91,"type":37},"2026-02-05",{"date":93,"type":37},"2024-05-07",{"date":95,"type":21},"2042-09-30",{"name":97,"class":44},"W.L.Gore & Associates",90,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":16,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":69},"100606103","targeted-abdominal-ct-in-conjunction-with-lung-cancer-screening-100606103","NCT07171190","Targeted Abdominal CT in Conjunction With Lung Cancer Screening","Targeted Abdominal CT in Conjunction With Lung Cancer Screening - a Pilot Study (TACTICAL1): a Randomised Controlled Pilot Study of Adding Abdominal Non-contrast CT to Lung Cancer Screening CT Thorax Amongst High Lung Cancer Risk Ever-smokers Aged 55-70.","TACTICAL1","1. For the individual level randomisation to invitation control or invitation intervention\n\n   Inclusion criteria: To be randomised at the individual level to receive an invitation letter for LCS (standard of care; invitation control) versus invitation letter for LCS with potential for an additional abdominal scan (invitation intervention):\n   * Be eligible to be invited to the first round of a West Yorkshire and Harrogate LCS or a Humber and North Yorkshire Cancer Alliance LCS (i.e. have been identified as a smoker or ex-smoker and registered as living within the relevant LCS catchment area).\n   * Be registered with a GP in England.\n   * Be aged 55-70 years 364 days old at the date of invitation.\n\n   Exclusion criteria\n\n   • None\n2. Eligibility criteria for the cluster level randomisation to scan intervention or scan control\n\n   Inclusion criteria a): To be eligible for the cluster level randomisation the participant must:\n   * Have been individually randomised to the invitation intervention arm\n   * Have booked in for a LCS assessment\n\n   Inclusion criteria b): To receive the CT Thorax plus ANCCT, the participant must:\n   * Have been randomised to the scan intervention cluster\n   * Be invited to attend for a LDCT Thorax based upon scores on either PLCOM2012 or Liverpool Lung Project (LLP) risk prediction models (PLCOM2012 risk of ≥1.51% over six years or LLPver2 five-year risk of ≥2.5%)14 during the LCS assessment.\n   * Have attended the lung scan appointment\n   * Have given electronic or written informed consent to participate\n\n   Exclusion criteria\n\n   Existing LCS exclusion criteria:\n   * Participant does not have capacity to give consent (standard criteria for assessing capacity apply).\n   * Weight or physical size exceeds restrictions for scanner (\\>200kg).\n   * Participant unable to lie flat.\n   * Poor physical fitness such that treatment with curative intent would be contra-indicated.\n   * Participants who have had a full CT Thorax that meets the image reconstruction parameters of the programme in the last 12 months are not excluded from the lung screening programme, but would have their CT Thorax appointment deferred until 12 months have elapsed since that last scan, provided they still meet all inclusion criteria and have no exclusion criteria - if the deferred appointment is within the timeframe for TACTICAL1, they remain eligible but if deferred appointment is outside the timeframe for TACTICAL1 they would not be eligible.\n\n   Additional TACTICAL1 exclusion criteria:\n\n   • Had an abdominal CT in the previous 12 months or has one booked within the next 3 months.\n   * For HNY, this is checked before the LCS assessment. Therefore, participants will be excluded before the LCS assessment.\n   * For WYH, this is only checked after the LCS assessment. Therefore, anyone having had an abdominal CT in the previous 12 months or with one booked within the next 3 months will be excluded at this point (see 8.6).\n3. Eligibility criteria for the process evaluation Health care professionals: Healthcare professionals involved in the delivery of LCS in any of the study areas who agree to take part.\n\nParticipants: People individually randomised to the invitation intervention arm who attend the LCS assessment or the scanning unit within the study period and who agree to be interviewed.",true,"55 Years","70 Years",{"count":111,"type":21},6272,[24],"Early detection through screening can improve cancer survival by identifying it when it's most treatable. The NHS now offers Lung Cancer Screening (LCS) assessments to people aged 55-74 who have ever smoked. Those at higher risk of lung cancer are offered a lung scan.\n\nThis group also has a high risk of developing abdominal cancers, such as kidney cancer. A recent study explored whether it would be feasible to extend the lung scan to include the abdomen. Results showed most participants supported this addition, and the number of serious findings was similar to those detected in UK breast or bowel cancer screening programmes.\n\nHowever, the abdominal scan was only offered on the day of the lung scan, giving little time for people to consider their decision. The process also added too much time to be practical for widespread implementation.\n\nThis new study will:\n\n* Test whether mentioning the possible abdominal scan in the initial LCS invitation affects participation in LCS assessments.\n* Test new processes to assess if the abdominal scan can be added to the lung scan with minimal extra time.\n* Check if participants can be split between the lung scan only group and lung and abdominal scan group using an approach called 'cluster randomisation'. This will be important in case a bigger trial is needed.\n* See whether the additional processes are acceptable\n\nPeople aged 55-70 who are invited to the lung cancer screening will be eligible to take part in this study. Only those who are found to be at a high risk of lung cancer after their assessment, and therefore offered a lung scan, will be offered the abdominal scan, provided they have not had an abdominal scan in the previous 12 months or one booked in the next 3 months.\n\nThis study will take place in two existing lung cancer screening locations in Yorkshire.",[115,116,27,117],"Renal Cell Carcinoma (Kidney Cancer)","Kidney Cancers","Renal Stones",[119,120,121,122,123,124,125],"Screening","NHS Lung Cancer Screening","Kidney cancer","Abdominal cancer","Lung cancer","Abdominal Aortic Aneurysms (AAA)","Abdominal screening","2025-12-12",{"date":128,"type":37},"2025-12-19",{"date":130,"type":37},"2025-11-11",{"date":132,"type":21},"2027-10",{"name":134,"class":135},"University of Cambridge","OTHER",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100444216","jaguar-trial-objective-analysis-to-gauge-evar-outcomes-through-randomization-100444216","NCT05064540","JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization","JAGUAR","Inclusion Criteria:\n\n* Adult age 21 and older\n* Subjects with minimum of 2 year life expectancy\n* Subjects have signed the informed consent document\n* Subjects with unruptured infrarenal AAA who are assessed by the Investigator to be eligible for endovascular Abdominal Aortic Aneurysm Repair with the trial devices.\n* Patient must be able and willing to comply with all required follow-up exams.\n\nExclusion Criteria:\n\n* Currently participating in another trial where the primary endpoint has not been reached yet.\n* Known allergy to any of the device components\n* Pregnant (females of childbearing potential only)\n* Known connective tissue disorders\n* Known active infection\n* Subjects with pre-existing EVAR, i.e., in need of repair\u002Fintervention of a previously failed EVAR.\n* Patient has other medical, social, or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.",{"count":144,"type":21},450,[24],"Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints.\n\nPatients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).",[148,27],"AAA",[150],"randomized","2025-06-05",{"date":153,"type":37},"2025-06-08",{"date":155,"type":37},"2021-09-20",{"date":157,"type":21},"2031-03",{"name":159,"class":44},"Endologix",29,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":168,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":185,"locationsCount":4},"100579951","virtual-prehabilitation-for-patients-undergoing-abdominal-aortic-aneurysm-repair-100579951","NCT06830967","Virtual Prehabilitation for Patients Undergoing Abdominal Aortic Aneurysm Repair","VPAR","Inclusion Criteria:\n\n* Participants older than 50 years of age awaiting elective open AAA repair with AAA diameter ≤6.9cm at the Halifax Infirmary Hospital between January 2025-December 2025. Participants must have the ability to give individual informed consent.\n\nExclusion Criteria:\n\n* Participants undergoing thoracic, thoracoabdominal and\u002For perivisceral AAA repair.\n* Participants with ruptured or symptomatic AAA.\n* Participants with AAA maximal diameter ≥7cm.\n* Physical inability to exercise: severe osteoarthritis, musculoskeletal or neurological impairment that precludes exercise.\n* Contraindication to exercise: rest systolic blood pressure ≥ 180 mmHg and\u002For diastolic ≥ 100 mmHg, uncontrolled atrial or ventricular arrythmias or proven exercise induced arrhythmias, unstable angina, unstable or acute heart failure, severe symptomatic valvular stenosis, dynamic left ventricular outflow tract obstruction or other comorbidities that imply clinical instability.\n* Inability to have a support person present during exercise therapy.\n* Cognitive impairment that would impede understanding of study procedures or informed consent.","50 Years",{"count":170,"type":21},20,[24],"The time between diagnosis and operative intervention represents an untapped opportunity to optimize patient readiness for surgery and augment their function prior to undergoing a physiological stress, rather than purely recovering post-operatively. Vascular surgery patients are frail and primed to benefit from such interventions and upcoming surgery is a strong motivator for behavioral change. In this proposal, the investigators outline our vision for a prehabilitation program for patients undergoing elective open aortic aneurysm repair (AAA).\n\nParticipants scheduled to undergo AAA repair would receive, in addition to standard of care, 5 main interventions: exercise therapy; smoking cessation counseling and pharmacotherapy; nutritional counseling; psychological readiness planning and patient education. Exercise therapy will consist of 6 weeks of moderate exercise coordinated remotely through the cardiology rehabilitation program, whereas all other interventions will be consultations through videoconferencing or phone interactions. Outcomes of interest include morbidity, mortality, predictors of completion of program, exercise function and quality of life.\n\nThis study is a pilot feasibility project and the first step in the creation of a long-term program that will improve patient clinical outcomes, exercise capacity quality of life and hopefully become an model for prehabilitation for other institutions across the country and raise the standard of care for vascular surgery patients.",[174,175,27],"Abdominal Aortic Aneurysm","Prehabilitation",[148,177,178],"prehabilitation","abdominal aortic aneurysm","2025-02-13",{"date":181,"type":37},"2025-02-17",{"date":183,"type":21},"2025-03-01",{"date":66,"type":21},{"name":186,"class":135},"Nova Scotia Health Authority"]